Stephen J. Farr, Ph.D. is a co-founder of Zogenix, a member of its board of directors, and the company’s President and Chief Executive Officer. He has served as Chief Executive Officer since April 2015, leading the company’s strategy on drug development in rare neurological disorders. Dr. Farr served as Zogenix’s President and Chief Operating Officer since its founding in 2006, leading the development and FDA approval of the company’s first two drug products.Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006, with his last position being the company’s Sr. Vice President and Chief Scientific Officer, with responsibility for research and development and business development. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of biopharmaceutics. While there, he built an internationally recognized research group working in drug delivery science with a focus on pulmonary drug delivery.Dr. Farr is a member of the board of directors of three private companies, Oscillari, LLC, Flow Pharma, Inc. and Cerebral Therapeutics. He is author/co-author of over 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond. Dr. Farr received a BSc (Hons) Pharmacy degree from De Montfort University, UK and holds his Ph.D. degree in Pharmaceutics from the University of Wales.